Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Aug;23(9):1240-1247.
doi: 10.1111/1756-185X.13927. Epub 2020 Aug 25.

Risk of malignancy in Korean patients with primary Sjögren's syndrome

Juyeon Kang  1 , Hyoungyoung Kim  1 , Jinwook Kim  2 , Seongmi Choi  3 , Sun-Young Jung  4 , Eun Jin Jang  5 , Soo-Kyung Cho  1 , Yoon-Kyoung Sung  1
Affiliations
Comparative Study

Risk of malignancy in Korean patients with primary Sjögren's syndrome

Juyeon Kang et al. Int J Rheum Dis. 2020 Aug.

Abstract

Objectives: To evaluate the risks of overall and site-specific malignancies in Korean patients with primary Sjögren's syndrome (pSS).

Methods: Using the Korean nationwide healthcare claims database, we constructed a retrospective cohort for prevalent pSS aged over 50 years. After enrollment between January 2012 and December 2014, patients were followed until the development of any malignancy, or until December 2015. Crude incidence rates of malignancies of pSS patients were calculated, and their standardized incidence ratios (SIRs) for malignancies were calculated compared to those in knee osteoarthritis (OA) patients.

Results: A total of 6,359 pSS and 5,476,302 knee OA patients were included in this study. During follow-up (19,474 person-years [PYs]), 310 cases of solid malignancy (158.8/10,000 PYs) and 47 cases of hematologic malignancies (23.5/10,000 PYs) were observed in pSS patients. The risks of overall (SIR 1.30, 95% CI 1.16-1.43), solid (SIR 1.16, 95% CI 1.03-1.29), and hematologic malignancies (SIR 4.80, 95% CI 3.43-6.17) were increased in pSS patients. There was an elevated risk of site-specific malignancy in non-Hodgkin's lymphoma (NHL, SIR 6.45, 95% CI 4.05-8.83), multiple myeloma (SIR 4.88, 95% CI 2.00-7.76), and oropharynx (SIR 4.16, 95% CI 1.90-6.42). The risk of lung cancer was increased only in male pSS patients (2.50, 95% CI 1.02-3.99), while the risk of thyroid cancer was increased in female patients (1.44, 95% CI 1.04, 1.84).

Conclusion: In patients with pSS over age 50, the risk of solid cancers such as oropharynx, thyroid, and lung cancers is also increased in addition to NHL.

Keywords: hematologic malignancy; incidence; primary Sjögren's syndrome; solid malignancy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Manoussakis MN, Moutsopoulos HM. Sjögren's syndrome. Otolaryngol Clin North Am. 1999;32(5):843-860.
    1. Kruize AA, Hene RJ, van der Heide A, et al. Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum. 1996;39(2):297-303.
    1. Sandhya P, Kurien BT, Danda D, Scofield RH. Update on pathogenesis of Sjögren's syndrome. Curr Rheumatol Rev. 2017;13(1):5-22.
    1. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-134.
    1. Segal BM, Nazmul-Hossain AN, Patel K, Hughes P, Moser KL, Rhodus NL. Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(6):673-680.

Publication types

LinkOut - more resources